Acesso livre
Acesso livre

Alergia e Imunologia

Estudo laboratorial mostra que a estratégia de vacinação heteróloga AstraZeneca + Pfizer propicia uma imunogenicidade mais potente contra Covid comparada a estratégias homólogas AZ + AZ ou Pfizer + Pfizer.

23 Ago, 2021 | 13:16h

Safety, reactogenicity, and immunogenicity of homologous and heterologous prime-boost immunisation with ChAdOx1 nCoV-19 and BNT162b2: a prospective cohort study – The Lancet Respiratory Medicine

Comentário convidado: Heterologous ChAdOx1-nCoV19–BNT162b2 vaccination provides superior immunogenicity against COVID-19

Conteúdos relacionados:

Lab study shows heterologous AstraZeneca/Pfizer vaccination produces strong immune response against SARS-CoV-2 Delta variant.

RCT: Safety and immunogenicity of heterologous vs. homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine.

Another study shows increased immune response with heterologous Oxford-AstraZeneca/mRNA vaccination (vários artigos sobre o tema)

 

Comentário no Twitter

 

[Preprint] Eficácia da vacina da Pfizer contra a variante Delta diminui mais rapidamente do que a da AstraZeneca; ambas oferecem a mesma proteção depois de 4 meses.

20 Ago, 2021 | 12:35h

Impact of Delta on viral burden and vaccine effectiveness against new SARS-CoV-2 infections in the UK – University of Oxford

Comentários:

Vaccines Are Less Effective Against Delta—And Pfizer’s Protection Wanes Rapidly—But Are The Best Way To Protect Against Covid, Large Study Finds – Forbes

Expert reaction to preprint looking at the impact of the delta variant on vaccine effectiveness – Science Media Centre

Pfizer vaccine effectiveness declines faster than AstraZeneca – study – Evening Standard

 

Comentário no Twitter

 

Estudo do NIH mostra que não há nenhum benefício significativo do plasma convalescente para pacientes ambulatoriais de COVID-19 com sintomas iniciais.

19 Ago, 2021 | 12:29h

NIH study shows no significant benefit of convalescent plasma for COVID-19 outpatients with early symptoms – NIH News Releases

Estudo original: Early Convalescent Plasma for High-Risk Outpatients with Covid-19 – New England Journal of Medicine

 

Comentário no Twitter

 

Estudos: proteção da vacina diminui com o tempo em relação à infecção por COVID, mas a proteção contra hospitalização é duradoura.

19 Ago, 2021 | 12:27h

Studies: COVID vaccine protection waning against infection but not hospitalization – CIDRAP

Estudo 1: Sustained Effectiveness of Pfizer-BioNTech and Moderna Vaccines Against COVID-19 Associated Hospitalizations Among Adults — United States, March–July 2021 – CDC Morbidity and Mortality Weekly Report

Estudo 2: Effectiveness of Pfizer-BioNTech and Moderna Vaccines in Preventing SARS-CoV-2 Infection Among Nursing Home Residents Before and During Widespread Circulation of the SARS-CoV-2 B.1.617.2 (Delta) Variant — National Healthcare Safety Network, March 1–August 1, 2021 – CDC Morbidity and Mortality Weekly Report

Estudo 3: New COVID-19 Cases and Hospitalizations Among Adults, by Vaccination Status — New York, May 3–July 25, 2021 – CDC Morbidity and Mortality Weekly Report

 

Comentário no Twitter (fio – clique para saber mais)

 

Estudo laboratorial mostra que a vacinação heteróloga AstraZeneca/Pfizer produz uma forte resposta imune contra a variante delta do SARS-CoV-2.

18 Ago, 2021 | 13:06h

SARS-CoV-2 delta variant neutralisation after heterologous ChAdOx1-S/BNT162b2 vaccination – The Lancet

Conteúdos relacionados:

RCT: Safety and immunogenicity of heterologous vs. homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine.

Another study shows increased immune response with heterologous Oxford-AstraZeneca/mRNA vaccination (vários artigos sobre o tema)

 

Comentário no Twitter (fio – clique para saber mais)

 

FDA autoriza aplicação de dose adicional da vacina contra Covid-19 em indivíduos imunocomprometidos – As demais pessoas, já plenamente vacinadas, não precisam de dose adicional neste momento.

16 Ago, 2021 | 12:10h

Coronavirus (COVID-19) Update: FDA Authorizes Additional Vaccine Dose for Certain Immunocompromised Individuals – U.S. Food & Drug Administration

Comentários:

Statement on FDA Authorization of Supplemental Vaccine Dose for Immunocompromised Patients – Infectious Diseases Society of America

CDC, FDA recommend COVID booster for immune-compromised – CIDRAP

FDA authorizes additional dose of Covid-19 vaccine for the immunocompromised – STAT

The fine print: Understanding the new policy authorizing extra Covid vaccine doses for the immunocompromised – STAT

Covid booster: US approves third jab for the immunocompromised – BBC

CDC Committee Approves Third Covid-19 Shot For Immunocompromised People—Here’s Who Should Get One – Forbes

CDC Panel Recommends 3rd Vaccine Dose For Immunocompromised People – NPR

6 Things To Know If You’re Immunocompromised And Considering A 3rd Shot – NPR

CDC recommends third Covid-19 vaccine dose for certain immunocompromised people – CNN

 

Comentário no Twitter

 

Estudo sugere um potencial benefício de proteção das vacinas MMR e DTP na redução do risco de infecções graves por Covid-19.

16 Ago, 2021 | 11:56h

Protective heterologous T cell immunity in COVID-19 induced by the trivalent Measles-Mumps-Rubella and Tetanus-Diptheria-Pertussis vaccine antigens – Med

 

Comentário no Twitter

 

Opinião | Hora de uma abordagem inteligente das doses de reforço.

13 Ago, 2021 | 12:20h

Time for a Smart Approach to Boosters – Think Global Health

Estudo randomizado | Avaliação da vacina de mRNA da Moderna em adolescentes.

12 Ago, 2021 | 12:30h

Evaluation of mRNA-1273 SARS-CoV-2 Vaccine in Adolescents – New England Journal of Medicine

Conteúdos relacionados:

Phase 1/2 RCT: CoronaVac is well tolerated and safe and induces strong humoral responses in children and adolescents aged 3–17 years.

RCT: Pfizer-BioNTech Covid-19 vaccine shows 100% efficacy in adolescents – mainly transient mild-to-moderate reactogenicity was frequently observed, such as injection-site pain (in 79 to 86% of participants), fatigue (in 60 to 66%), and headache (in 55 to 65%).

 

Comentários no Twitter

 

Estudo randomizado | Terceira dose da vacina de mRNA da Moderna aumenta a imunidade em receptores de transplantes.

12 Ago, 2021 | 12:28h

Randomized Trial of a Third Dose of mRNA-1273 Vaccine in Transplant Recipients – New England Journal of Medicine

Editorial: Third Time’s a Charm — Covid-19 Vaccine Hope for Solid-Organ Transplant Recipients

Conteúdos relacionados:

Study: Among kidney transplant recipients who did not respond after 2 doses, a third dose of an mRNA-1273 vaccine induced a serologic response in 49% of patients.

Case series: Safety and immunogenicity of a third dose of SARS-CoV-2 vaccine in solid organ transplant recipients.

[Preprint] 3rd AstraZeneca shot gives strong immunity.

 

Comentários no Twitter

 

Mantenha-se atualizado em sua especialidade

 

Escolha quantas especialidades quiser.